The psychedelics landscape changes quickly. Whether large or small, every biotech company is looking for ways to further advance their research and product & services commercialization

Whether forward or back, stock splits are not intended to, nor should they, change the actual value of a company. Yet there are a few reasons why firms decide to “cut the pie” into different sized slices. One, for instance, is complying with listing requirements. 

The time seems to have come for Silo Pharma Inc. (OTCQB: SILO), …

Full story available on Benzinga.com